LEXINGTON, Mass.--(BUSINESS WIRE)--Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that 18 abstracts featuring research related to its marketed antibiotic and pipeline candidates were accepted for the 2011 joint meeting of the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) and the International Congress of Chemotherapy (ICC). Abstracts feature CUBICIN® (daptomycin for injection), and pipeline candidates CXA-201, which is being developed for the treatment of certain serious Gram-negative bacterial infections, including those caused by multi-drug resistant Pseudomonas aeruginosa, and CB-183,315, a potent, oral, bactericidal lipopeptide, which is being developed for the treatment of Clostridium difficile-associated diarrhea (CDAD). The 21st ECCMID/27th ICC congress will be held from May 7 to 10 in Milan, Italy.
